Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutational testing in the selection of patients for EGFR-targeted therapies.

Seminars in diagnostic pathology - 1 Nov 2008

Garcia Joaquin, Riely Gregory J, Nafa Khedoudja, Ladanyi Marc

Abstract excerpt

The small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and the anti-EGFR monoclonal antibodies have proven activity in lung and colorectal adenocarcinomas, respectively, but only a small fraction of patients exhibit significant responses. The observation that only a minority of patients respond to EGFR-targeted therapies, in combination with their toxicity and high costs, has driven...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Clinical Trials as Topic
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 19013894
DOI: 10.1053/j.semdp.2008.08.003

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutational testing in the selection of patients for EGFR-targeted therapies.PMID 19013894Read ↗

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?Semantic proximity Read ↗

KRAS mutation: should we test for it, and does it matter?Semantic proximity Read ↗

Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.Semantic proximity Read ↗

KRAS mutations predict response to EGFR inhibitors.Semantic proximity Read ↗

KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.Semantic proximity Read ↗

KRAS mutations as prognostic and predictive markers in non-small cell lung cancer.Semantic proximity Read ↗

KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue.Semantic proximity Read ↗

KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives.Semantic proximity Read ↗

Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics.Semantic proximity Read ↗

KRAS mutations in non-small cell lung cancer.Semantic proximity Read ↗

KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer.Semantic proximity Read ↗

EGFR and KRAS in colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.